Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Jun 07, 2018 10:18am
130 Views
Post# 28138966

RE:RE:Quick summary points from a very busy guy

RE:RE:Quick summary points from a very busy guy
palinc2000 wrote:
SPCEO1 wrote:
  1. At the annual meeting the company noted the following:
    1. They have about 100 patients on the drug after 2 ½ weeks after sales began – a very nice start
    2. The pace of new prescriptions coming in is accelerating
    3. About 25% of those insured by private insurance in the US are currently covered as reimbursement approvals have come faster than anticipated
    4. 250 clinics have submitted paperwork to be able to write Trogarzo prescriptions
    5. Medicare patients can now get Trogarzo (although this remains a complicated process at this point)
    6. About 20% of the Medicaid population is now covered by Trogarzo
    7. THERF is days away from gaining coverage for about 10% of expected patients who will eventually take Trogarzo via a program for poorer patients called ADAP
    8. Luc referred to this progress as “amazingly good”

100 patients in first 2.5 weeks
almost 7 weeks for the additional 100 
increasing pace? ???


I think the "accelerating" statement was likely uncharacteristic rashness. Some perspective. The drug had been on the market for 16 days. The whole process of getting payors on board was going very well as was the interest from clinics. I think thera can be forgiven for thinking the process was accelerating at that early stage. I'm not sure we should get too worried (yet) about trends over a few weeks its going to be a bumpy ride for sure. Overall the start is still pretty strong.

Bullboard Posts